Article Details

Redhill Biopharma announces completion of enrollment for oral opaganib phase 2/3 COVID-19 study

Retrieved on: 2021-06-08 00:00:00

Tags for this article:

Click the tags to see associated articles and topics

Redhill Biopharma announces completion of enrollment for oral opaganib phase 2/3 COVID-19 study. View article details on hiswai:

Excerpt

RedHill Biopharma Ltd. ("RedHill" or the "Company"), a specialty biopharmaceutical company, today announced that it has completed enrollment and ...

Article found on: www.news-medical.net

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up